Polymers for Solubility Enhancement Will Drive the Oral Solid Dosage Forms Market
Poor solubility has been a major challenge in the formulation development for oral solid dosage form (OSDF) pharmaceuticals, a preferred route for pharmaceutical consumption. Various methods have been researched to improve solubility of poorly soluble APIs and among these the use of polymers for solubility enhancement in solid dispersions is among the most popular.
Identifying the importance of the trend and to fulfil inadequately assessed market for polymers for solubility enhancement, global consulting and research firm Kline & Company is announcing the undertaking of a comprehensive study on Polymers for Solubility Enhancement in Pharmaceutical Oral Solid Dosage Forms: Global Market Analysis and Opportunities. The study will cover current and forecast demand by major products, supplier sales, and technical and market trends, as well as market opportunities and challenges for manufacturers of these polymers worldwide.
Oral administration is a natural means of consumption and is best for chronic drug therapy. In addition, the manufacturing of OSDF can be an advantage compared to other dosage forms; positively impacting the price of pharmaceutical products.
Nikola Matic, Industry Manager at Kline's Chemicals & Materials practice, states: “After having pushed in the direction of OSDFs for many years, the pharmaceutical industry now faces a dilemma stemming from the poor solubility of an increasing number of new drugs. Furthermore, of about 80–90% of products in the R&D pipeline are reported to be poorly soluble in water. As a result, this triggers low oral bioavailability and could in turn jeopardize the development of new drugs.”
Solubility is growing in importance and those who are able to capitalize on the potential that these enhancers bring to the table will see its inherent value. “Solubility enhancement is becoming a must for pharmaceutical companies and an area representing vast growth potential for chemical suppliers since tomorrow’s block-busters will most likely make use of one of the possible technologies to increase dissolution rate,” adds Matic.
This is a complex topic and today’s reality can quickly evolve into something different tomorrow as the industry experiences trends and innovations that influence its course. Kline’s Polymers for Solubility Enhancement in Pharmaceutical Oral Solid Dosage Forms: Global Market Analysis and Opportunities report will introduce all available technology and present their advantages and/or constraints and will focus on the polymers available for solubility enhancement through solid dispersion. The report will provide insights into the global market and regional specificities for solubility enhancement and provide a comprehensive overview of the markets’ present undertakings, and, most importantly, shed light on what lies ahead in the unknown future.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance